UVI5008: the first reversible, non-covalent Bruton's tyrosine kinase epi-inhibitor for B-cell malignancies [0.03%]
用于B细胞恶性肿瘤的首个可逆非共价型布鲁顿酪氨酸激酶表观遗传抑制剂UVI5008
Carmela Dell&#x;Aversana,G Sgueglia,C Massaro et al.
Carmela Dell&#x;Aversana et al.
Background: Chronic lymphocytic leukemia (CLL) can still be a therapeutic challenge; notwithstanding substantial progress in therapeutic approaches with small molecule inhibitors, the emergence of inhibitor resistance and...
Allogeneic stem cell transplantation for major T-cell lymphoma entities: an analysis of the EBMT-lymphoma working party [0.03%]
骨髓移植治疗T淋巴瘤：欧洲血液及骨髓移植组织淋巴瘤专题组的分析结果
Evgenii Shumilov,Maud Ngoya,Philipp Berning et al.
Evgenii Shumilov et al.
Background: Allogeneic hematopoietic stem cell transplantation (allo-SCT) is an established treatment for peripheral T-cell lymphoma (PTCL), particularly for patients with relapsed/refractory (r/r) disease. We aimed to re...
IL-5 CAR-T cell therapy induces effective remission in hypereosinophilic disorders [0.03%]
携带IL-5的CAR-T细胞疗法能有效诱导高嗜酸性粒细胞综合征患者的缓解症状
Youqian Wu,Ruiqi Zhang,Beibei Sun et al.
Youqian Wu et al.
Background: Clonal and pathogenic eosinophil expansion in hypereosinophilic disorders (e.g., refractory hypereosinophilic syndrome (HES) and chronic eosinophilic leukemia (CEL)) remains an unmet therapeutic challenge, wit...
The distinct roles of ROS in tumor immunity: from mechanisms to immunotherapeutic applications [0.03%]
活性氧在肿瘤免疫中的不同作用：从机制到免疫治疗应用
Jiayi Li,Chen Huang,Pan Tang et al.
Jiayi Li et al.
Reactive oxygen species (ROS) are crucial signaling molecules that regulate diverse biological processes. In cancer, this duality gives rise to a central paradox. Moderate ROS levels support tumor proliferation and foster an immunosuppressi...
Implementing generative artificial intelligence in precision oncology: safety, governance, and significance [0.03%]
在精准肿瘤学中实施生成式人工智能：安全性、治理和意义
Ryuji Hamamoto,Takafumi Koyama,Satoshi Takahashi et al.
Ryuji Hamamoto et al.
The paramount challenge in precision oncology lies in further improving quality of life and response rates for individual patients. Efforts toward these goals are steadily expanding the scope of clinical implementation, despite ongoing chal...
Lung cancer vaccines to enhance immune checkpoint inhibitor therapy: evidence and future perspectives [0.03%]
肺癌疫苗与免疫检点抑制剂治疗联合使用的证据和未来前景
Zhiting Tang,Linjun Zha,Ruqiang Liang et al.
Zhiting Tang et al.
Immune checkpoint inhibitors (ICIs) have transformed the treatment landscape of lung cancer over the past decade, markedly improving antitumor responses, overall survival, and quality of life. However, durable clinical benefit is achieved i...
BCMA-CD19 armored compound CAR T cells in systemic lupus erythematosus: extended follow-up of a phase 1 clinical trial [0.03%]
靶向BCMA和CD19的复合型装甲CAR-T细胞治疗系统性红斑狼疮：一项I期临床试验的长期随访结果
Ming Hong,Mingxia Wang,Ronghao Zeng et al.
Ming Hong et al.
CD19 CAR T-cells have shown promise in treating systemic lupus erythematosus (SLE), however, relapses demonstrate persistently elevated autoantibodies characteristic of CD19-negative long-lived plasma cells (LLPCs). Alternatively, ICG318, a...
Chun Wu,Xuefei Liu,Boxi Zhao et al.
Chun Wu et al.
The survival mechanisms of circulating tumor cells (CTCs) remain poorly understood while these rare cell populations transit through the blood stream and colonize distant organs including the brain. Using single-cell RNA-seq of microfluidic...
Patterns, risk factors and management of CD19-directed chimeric antigen receptor T-cell therapy failure in CNS lymphoma [0.03%]
CD19导向的嵌合抗原受体T细胞治疗CNS淋巴瘤失败的模式、危险因素及处理措施
Leon D Kaulen,Philipp Karschnia,Sofia Doubrovinskaia et al.
Leon D Kaulen et al.
Background: CD19-directed chimeric antigen receptor T-cell therapy (CD19-CAR) has yielded encouraging efficacy in CNS lymphomas (CNSL), but most patients ultimately experience progressive disease (PD). Risk factors, progr...
Elie Cousin,Agathe Picard,Maria Oundjian et al.
Elie Cousin et al.
The advent of next-generation high-throughput sequencing and precision medicine has allowed the identification of recurrent genetic events of vital interest for leukemic cells and for the management of patients with leukemia, since it has a...